GLP-1 receptor agonists were originally developed for type 2 diabetes. That's where drugs like Ozempic got their start. But once researchers noticed patients losing substantial weight on these medications, the pharmaceutical companies pursued separate FDA approvals specifically for obesity. The result is a confusing situation where the same active ingredient — semaglutide, for example — is sold under different brand names for different conditions.
Same Drug, Different Label
The clearest example is semaglutide. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management. Both are injectable semaglutide made by Novo Nordisk. The same split exists with tirzepatide: Mounjaro treats diabetes, while Zepbound targets weight loss.
This isn't just a branding exercise. The dosing schedules differ. Wegovy ramps up to 2.4 mg per week, while Ozempic tops out at 2 mg. Zepbound and Mounjaro share the same maximum dose (15 mg), but the titration protocols and prescribing guidelines are tailored to each condition.
Why the Distinction Matters for Insurance
Insurance coverage is where this gets practical. Most commercial insurance plans cover diabetes medications without much pushback — type 2 diabetes is a well-established diagnosis with clear treatment guidelines. Weight loss medications are a different story. Many insurers still classify obesity drugs as "lifestyle" treatments and exclude them from coverage, even though obesity is recognized as a chronic disease by every major medical organization.
Medicare is a good example of the gap. It covers Ozempic for diabetes patients but, as of early 2026, still doesn't cover Wegovy for weight loss. Some state Medicaid programs have started covering anti-obesity medications, but it's inconsistent. If cost is a concern, our pricing guide breaks down what you can expect to pay.
Off-Label Prescribing
Because of coverage gaps, some doctors prescribe Ozempic off-label for weight loss. This is legal — doctors can prescribe any FDA-approved drug for any condition they believe is medically appropriate. But there are trade-offs. You might get a lower dose than you'd receive with Wegovy, and if your insurer audits the claim, you could face problems.
Some clinics are upfront about this approach. Others won't do it at all. It's worth asking directly when you're shopping for a provider. You can search our clinic directory and ask during a consultation what their prescribing approach is.
Eligibility Criteria Differ
For diabetes, the prescribing criteria are straightforward: you have type 2 diabetes, and your doctor decides a GLP-1 is appropriate for blood sugar management. For weight loss, FDA guidelines require a BMI of 30 or higher — or 27+ with at least one weight-related condition like high blood pressure, sleep apnea, or high cholesterol. Check our BMI calculator if you're not sure where you stand.
Patients with both diabetes and obesity are in a unique position. Their doctor might prescribe a diabetes-labeled GLP-1 that also helps with weight, getting insurance to cover a medication that accomplishes both goals. This is actually a common and legitimate prescribing strategy.
Which One Should You Ask About?
If you have type 2 diabetes, your endocrinologist or primary care doctor will likely start with the diabetes-approved version. If weight loss is your primary goal and you don't have diabetes, you'll want a provider who prescribes Wegovy or Zepbound specifically. The active ingredients work the same way in your body — they slow gastric emptying, reduce appetite, and act on brain receptors that control hunger. The real differences come down to dosing, insurance coding, and which condition your doctor documents as the primary diagnosis.